Republican chairman wants FTC to review mergers of drug price negotiators

Republican chairman wants FTC to review mergers of drug price negotiators

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenConservative groups defend tech from GOP crackdown Overnight Health Care — Presented by PCMA — Sanders unveils new Medicare for all bill with backing from other 2020 Dems | White House slams Sanders' rollout | Drugmakers, 'middlemen' point fingers on insulin pricing House votes to reinstate Obama-era net neutrality rules MORE (R-Ore.) on Friday requested a review of mergers by drug price negotiators, questioning whether the moves had driven up costs for patients.

Walden wrote to the Federal Trade Commission requesting a review looking at recent mergers of companies known as pharmacy benefit managers (PBMs), which negotiate prices with drug manufacturers.

In the letter, Walden said that while there is “conflicting information” on the impact of these mergers, he fears some companies could have “used their market power to try to increase their profits and that PBMs have encouraged higher list prices for prescription drugs that increase co-pays for patients.”

ADVERTISEMENT

The letter comes amid increased scrutiny of high drug prices. President TrumpDonald John TrumpHouse Dems demand Barr cancel 'inappropriate' press conference on Mueller report DOJ plans to release 'lightly redacted' version of Mueller report Thursday: WaPo Nadler accuses Barr of 'unprecedented steps' to 'spin' Mueller report MORE has been calling out drug companies by name on Twitter, and his administration recently floated the possibility of allowing the importation of drugs to increase competition when there are price spikes.

The letter from Walden, which was also signed by GOP Reps. Gregg HarperGregory (Gregg) Livingston HarperCongress sends bill overhauling sexual harassment policy to Trump's desk Dems cry foul in undecided N.C. race Mississippi New Members 2019 MORE (Miss.) and Michael BurgessMichael Clifton BurgessOvernight Health Care — Presented by PCMA — Sanders to roll out 'Medicare for all' bill | Dems target Juul over Altria ties | Measles cases spike nationwide GOP rep who supports lowering voting age: 'It's on us' if 16-year-olds vote Democratic Divisions emerge over House drug price bills MORE (Texas), focuses more on PBMs, which have also come under scrutiny for a lack of transparency in setting prices.

Some drug pricing advocates, however, say the focus should be on drug companies that initially set the prices.